Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 47

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 47
---
 of data developed through any clinical trial than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties, such as CROs, may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our clinical trial. We may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a CRO may lead us to seek to terminate the relationship and use an alternative service provider. However, making any change may be costly and may delay ongoing trials, if any, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable cost. Even though we anticipate relying on CROs in the future, we will likely have to devote substantial resources and rely on the expertise of our employees to manage the work being done by the CROs. We and our management team have experience in managing clinical trials being executed on our behalf by CROs based on three clinical studies. Therefore, we cannot guarantee that our employees will manage such studies effectively in the future. We expect to depend on existing and future collaborations with third parties for the development of some of our product candidates. If those collaborations are not successful, we may not be able to complete the development of these product candidates. Collaborations involving our product candidates pose the following risks to us:

| ● | collaborators                                                                             
 have significant discretion in determining the efforts and resources that they will apply 
 to these collaborations;                                                                  |

| ● | collaborators                                                                                   
 may not pursue development and commercialization of our product candidates or may elect not     
 to continue or renew development or commercialization programs based on clinical trial results, 
 changes in the collaborator’s strategic focus or available funding, or external factors         
 such as an acquisition that diverts resources or creates competing priorities;                  |

| ● | collaborators                                                                              
 may delay clinical trials, provide insufficient funding for a clinical trial program, stop 
 a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or  
 require a new formulation of a product candidate for clinical testing;                     |

| ● | collaborators                                                                                    
 could independently develop, or develop with third parties, products that compete directly       
 or indirectly with our product candidates if the collaborators believe that competitive products 
 are more likely to be successfully developed or can be commercial